Mechanism of Action and Therapeutic Potential of Xanthohumol in Prevention of Selected Neurodegenerative Diseases

被引：0

作者：

Dlugosz, Anna ^{[1
]}

Blaszak, Blazej ^{[1
]}

Czarnecki, Damian ^{[2
]}

Szulc, Joanna ^{[1
]}

机构：

[1] Bydgoszcz Univ Sci & Technol, Fac Chem Technol & Engn, Dept Food Ind Technol & Engn, PL-85326 Bydgoszcz, Poland

[2] Nicolaus Copernicus Univ Torun, Fac Hlth Sci, Dept Prevent Nursing, Coll Med Bydgoszcz, PL-85821 Bydgoszcz, Poland

来源：

MOLECULES | 2025年 / 30卷 / 03期

关键词：

Alzheimer's disease; amyotrophic lateral sclerosis; anti-inflammatory; antioxidant; neurodegenerative diseases; Parkinson's disease; xanthohumol; OXIDATIVE STRESS; ANTIOXIDANT ACTIVITY; INFLAMMATORY RESPONSES; NATURAL COMPOUNDS; PHARMACOKINETICS; NEUROGENESIS; HOPS; PRENYLFLAVONOIDS; INHIBITION; PATHWAYS;

D O I：

10.3390/molecules30030694

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Xanthohumol (XN), a bioactive plant flavonoid, is an antioxidant, and as such, it exhibits numerous beneficial properties, including anti-inflammatory, antimicrobial, and antioxidative effects. The main dietary source of XN is beer, where it is introduced through hops. Although the concentration of XN in beer is low, the large quantities of hop-related post-production waste present an opportunity to extract XN residues for technological or pharmaceutical purposes. The presented study focuses on the role of XN in the prevention of neurodegenerative diseases, analyzing its effect at a molecular level and including its signal transduction and metabolism. The paper brings up XN's mechanism of action, potential effects, and experimental and clinical studies on Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Additionally, challenges and future research directions on XN, including its bioavailability, safety, and tolerance, have been discussed.

引用

页数：23

共 131 条

[1]

Gawel M., Potulska-Chromik A., Neurodegenerative diseases: Alzheimer’s and Parkinson’s disease, Postępy Nauk Med, 7, pp. 468-476, (2015)

[2]

Gitler A.D., Dhillon P., Shorter J., Neurodegenerative Disease: Models, Mechanisms, and a New Hope, Dis. Models Mech, 10, pp. 499-502, (2017)

[3]

Dugger B.N., Dickson D.W., Pathology of Neurodegenerative Diseases, Cold Spring Harb. Perspect. Biol, 9, (2017)

[4]

Bai R., Guo J., Ye X.-Y., Xie Y., Xie T., Oxidative Stress: The Core Pathogenesis and Mechanism of Alzheimer’s Disease, Ageing Res. Rev, 77, (2022)

[5]

Sies H., Berndt C., Jones D.P., Oxidative Stress, Annu. Rev. Biochem, 86, pp. 715-748, (2017)

[6]

Szulc J., Czaczyk K., Dobrowolska A., Gozdecka G., Blaszak B., Elicitation as a Process of Enhancing Bioactive Compounds Concentration in Sprouts, Processes, 12, (2024)

[7]

Ramanan M., Sinha S., Sudarshan K., Aidhen I.S., Doble M., Inhibition of the Enzymes in the Leukotriene and Prostaglandin Pathways in Inflammation by 3-Aryl Isocoumarins, Eur. J. Med. Chem, 124, pp. 428-434, (2016)

[8]

Sudarshan K., Boda A.K., Dogra S., Bose I., Yadav P.N., Aidhen I.S., Discovery of an Isocoumarin Analogue That Modulates Neuronal Functions via Neurotrophin Receptor TrkB, Bioorg. Med. Chem. Lett, 29, pp. 585-590, (2019)

[9]

Neumann H.F., Frank J., Venturelli S., Egert S., Bioavailability and Cardiometabolic Effects of Xanthohumol: Evidence from Animal and Human Studies, Mol. Nutr. Food Res, 66, (2022)

[10]

Stevens J.F., Page J.E., Xanthohumol and Related Prenylflavonoids from Hops and Beer: To Your Good Health!, Phytochemistry, 65, pp. 1317-1330, (2004)

← 1 2 3 4 5 6 7 8 9 10 →